Shanghai RAAS Blood Products Co Ltd Class A Financial Flexibility Index
Shanghai RAAS Blood Products Co Ltd Class A financial flexibility index. Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Financial Flexibility Index of -0.13x as of December 2025. Free cash flow of CN¥-672.37 Million (operating CF CN¥-843.75 Million minus capex CN¥171.38 Million) represents 0% of total liabilities (CN¥5.33 Billion). See 002252 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
Financial flexibility index of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025. Historical Financial Flexibility Index trend for Shanghai RAAS Blood Products Co Ltd Class A across 21 annual periods. Check 002252 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Shanghai RAAS Blood Products Co Ltd Class A Financial Flexibility Index by Year (2005–2025)
Shanghai RAAS Blood Products Co Ltd Class A financial flexibility index by year from 2005 to 2025. Year-by-year free cash flow to debt coverage for Shanghai RAAS Blood Products Co Ltd Class A. For the full cash flow conversion analysis, see how efficiently does Shanghai RAAS Blood Products Co Ltd Clas generate cash.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.05x | CN¥274.12 Million | CN¥-104.89 Million | CN¥5.34 Billion | ▲ +215.9% |
| 2024 | -0.04x | CN¥-74.91 Million | CN¥-482.06 Million | CN¥1.69 Billion | ▼ -103.7% |
| 2023 | 1.20x | CN¥2.73 Billion | CN¥2.28 Billion | CN¥2.28 Billion | ▲ +0.9% |
| 2022 | 1.19x | CN¥1.95 Billion | CN¥1.73 Billion | CN¥1.64 Billion | ▲ +5.5% |
| 2021 | 1.12x | CN¥1.50 Billion | CN¥1.29 Billion | CN¥1.33 Billion | ▼ -71.2% |
| 2020 | 3.91x | CN¥1.42 Billion | CN¥1.17 Billion | CN¥363.74 Million | ▲ +37.6% |
| 2019 | 2.84x | CN¥1.03 Billion | CN¥872.69 Million | CN¥361.95 Million | ▲ +236.1% |
| 2018 | 0.84x | CN¥419.44 Million | CN¥262.50 Million | CN¥496.56 Million | ▲ +291.1% |
| 2017 | 0.22x | CN¥426.60 Million | CN¥268.76 Million | CN¥1.98 Billion | ▼ -58.9% |
| 2016 | 0.53x | CN¥785.71 Million | CN¥638.22 Million | CN¥1.50 Billion | ▼ -51.2% |
| 2015 | 1.08x | CN¥907.81 Million | CN¥762.42 Million | CN¥843.64 Million | ▲ +53.0% |
| 2014 | 0.70x | CN¥531.02 Million | CN¥465.96 Million | CN¥755.16 Million | ▲ +741.2% |
| 2013 | 0.08x | CN¥39.57 Million | CN¥-90.11 Million | CN¥473.37 Million | ▼ -96.2% |
| 2012 | 2.19x | CN¥413.16 Million | CN¥263.46 Million | CN¥188.79 Million | ▼ -49.3% |
| 2011 | 4.31x | CN¥354.82 Million | CN¥178.03 Million | CN¥82.26 Million | ▲ +47.7% |
| 2010 | 2.92x | CN¥289.42 Million | CN¥200.21 Million | CN¥99.12 Million | ▲ +2.1% |
| 2009 | 2.86x | CN¥177.01 Million | CN¥116.01 Million | CN¥61.88 Million | ▲ +59.7% |
| 2008 | 1.79x | CN¥136.87 Million | CN¥107.64 Million | CN¥76.42 Million | ▲ +22.2% |
| 2007 | 1.47x | CN¥200.17 Million | CN¥175.71 Million | CN¥136.53 Million | ▲ +276.0% |
| 2006 | 0.39x | CN¥65.67 Million | CN¥53.58 Million | CN¥168.39 Million | ▼ -47.5% |
| 2005 | 0.74x | CN¥75.71 Million | CN¥54.02 Million | CN¥101.93 Million | — |